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ABSTRACT
I ntroduction and Objective : Prosthetic hip-associated cobalt toxicity (PHACT) is a rare
cause of cobalt toxicity from metal-on metal (MoM) total hip prosthesis. There are few
reports of PHACT and only one case report from our review that reported tremor as a
presenting symptom.7
Case Presentation: This is a report of a 44 year old male with history of hip replacement.
He presented to PCP with progressive worsening of muscle weakness, fatigue and
tremor of two months duration. After an extensive work up was performed and
reviewing current literature, serum cobalt level was eventually performed and was
found to be high. Resolution of the symptoms with concomitant decrease in serum
cobalt was noted.
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Discussion: PHACT being a diagnosis which is rare and done by exclusion, it is important
to make it a part of the differential diagnosis. As our patient also has the diagnosis of
Charcot Marie Tooth, it is important to prevent anchoring heuristic bias and evaluate the
patient from fresh eyes especially with a history of MoM device placement.
Conclusion: The symptoms did resolve on removing the MoM device which does imply
that PHACT can be regarded closer to a fact when compared to a fiction.
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INTRODUCTION

OBJECTIVE

Prosthetic hip-associated cobalt toxicity (PHACT) is
a rare cause of cobalt toxicity from metal-on metal
total hip prosthesis. Symptoms of cobalt toxicity
include sensorineural hearing impairment, vision loss,
cognitive impairment, cardiac failure, neuropathy,
and hypothyroidism.

PHACT is a rare disease and tremor has been reported
in only one case.7 This report is to highlight this
manifestation of this rare disease and the importance
of considering PHACT in any patient presenting with
a tremor, months to years after the implantation of a
MoM device.

The following criteria have been suggested for the
diagnosis of PHACT:
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1. Elevated cobalt levels due to a prosthetic hip.
2. At least two levels consistent with cobalt toxicity.
3. Exclusion of other etiologies.
MARSHALL JOURNAL OF

MEDICINE
™

Expanding Knowledge to Improve Rural Health.

A 44 year old male with history of hip replacement
presented to PCP with progressive worsening of
muscle weakness, fatigue and tremor of two months
duration.
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The patient has past medical history of: Charcot
Marie Tooth (CMT) type 1 A, Hypogonadism and Hip
Osteoarthritis and had foot surgery for CMT and Hip
replacement with a metal on metal prosthesis five
years back.
PHYSICAL EXAM
Vital signs, chest, abdomen and heart exam were
within the normal limits.
New onset high frequency low amplitude,
intentional tremor of truncal and upper extremities
is noted, Strength was decreased all over as well as
proprioception and vibration in feet; Patient was
chronically areflexic from his CMT.
WORKUP
After exhaustive work up and referrals, worsening
of CMT, androgen deficiency and factitious disorder

were considered.
Adequate testosterone replacement and thorough
psychiatric evaluation didn’t improve the tremor.
Meanwhile, patient started complaining of hip pain,
with his history of metal on metal hip joint Prosthesis
and refractory tremor; cobalt levels were checked.
IMAGING AND LABORATORY STUDIES
Cobalt: 37 ng/ml (N = 0.0-0.9)
MRI brain was negative.
Nerve conduction study: severe chronic hereditary
demyelinating neuropathy such as CMT 1A. However
the temporal dispersion noted suggests an acquired
inflammatory component.
Testosterone, Albumin and Chromium levels were
within normal limits.

Right Hip MRI showing metallic artifact indicating a Metal on Metal
Hip Prosthesis.
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INTERVENTION
Removal of metal on metal hip prosthesis, it was
replaced with Polyethylene and Oxinium Prosthesis.
Laboratory work and exam findings twelve weeks
after intervention:
Cobalt: 2.6 ng/ml (N= 0.0- 0.9)
Complete resolution of tremor was noted.
DISCUSSION
While the use of metal-on-metal (MoM) hip devices
in the USA is declining due to safety concerns,1
it is estimated that about 1 million MoM devices
have been implanted worldwide in the past two
decades.2 All such devices in the USA contain
cobalt alloys. Normal wear and tear experienced by
these devices has demonstrated release of metal
microparticles and ions into systemic circulation.4
Concerns about device safety have caused product
recalls and clinical guidelines by the Food and Drug
Administration.5
This case of prosthetic hip-associated cobalt toxicity
(PHACT) is significant for a few reasons. First of all,
little is known about PHACT and few cases have
been reported. A systematic review carried out by
Devlin et al in 2013 found only 10 cases, which met
their criteria.1 It is hypothesized by the authors that
the prevalence of suspected PHACT will increase
in the coming years due to a growing population
of patients who have had MoM devices for many
years as well as an increased index of suspicion in
treating physicians. In this regard, this case certainly
highlights the likelihood of PHACT being initially
overlooked as a diagnosis.
Perhaps most significant about this case was the
patient’s chief complaint of tremor. Of the ten cases
reported by Devlin et al, nine of them had neurologic
manifestations yet only one of them presented
with a tremor. In a 2012 review of neurological
involvement of cobalt toxicity by all routes of
ingestion by Catalini et al, only one out of eleven
cases (the same case in fact) demonstrated tremor.6,7
Neurologic dysfunction due to cobalt toxicity by any
route (the historic routes being cobaltous chloride
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infusion for hematopoiesis, industrial exposure, and
consumption of beer containing excess cobalt8)
presents similarly to that seen in PHACT. The most
common neurotoxic symptoms include hearing
loss, visual impairment, and polyneuropathy. The
mechanism by which cobalt causes neurotoxicity
is controversial and likely multifactorial. Cobalt is
known to be directly cytotoxic to neurons, disrupt
oxidative phosphorylation, alter neurotransmitter
regulation, phosphorylate MAP kinases, and repress
the p53 gene.6 And more recently, metal ions on
cell- mediated immunity, lymphocyte reactivity and
chemokine secretions have been demonstrated
among other actions.10,11,12
Tremors are quite common with an estimated
worldwide prevalence of essential tremor alone
reaching as high as 5 percent of the population.9
Also, CMT type 1A Neurological manifestation
does include kyphoscoliosis, postural hand tremor,
hypoacousia, motor and sensory loss and areflexia of
upper and lower extremities, pes cavus.13 This case,
however, displayed a temporal relationship of device
implantation followed by clinical symptoms as well
as serum abnormalities, which were both relieved by
removal of the device.
The discussion would not be completed if reports
against PHACT were not reviewed. Retrospective and
case studies measuring ERY have reported evidence
against implant derived cobalt toxicity.14 Also in a
self-reported cross sectional study, the neurological
symptoms did not correlate to the elevated cobalt
levels.15 This could be attributed to the rarity of this
condition and the lack of concrete guidelines.
This case is a good example of anchoring heuristic
bias and how it can affect patient outcomes.
This patient’s known diagnoses of CMT as well as
hypogonadism lead to exhaustive workup and
referrals. As the patient’s condition failed to improve,
he underwent both testosterone replacement
and psychiatric therapy for possible diagnoses
of androgen deficiency and factitious disorder
respectively.
CONCLUSION
This original case report describes a novel
presentation of a poorly understood and rarely
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reported phenomenon. The diagnosis of PHACT can
be complicated as its etiology and symptoms span
numerous clinical specialties. During the evaluation
of tremors, especially in individuals with MoM
implantation, PHACT should be considered as a
differential diagnosis. Additional studies and reports
would be beneficial in forming better guidelines for
diagnosis and treatment to improve patient care.
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